Aim To study the therapeutic effects of recombinant huma n interleukin 1 receptor antagonist (rhIL-1ra) on type Ⅱ collagen-induced arthr itis(CIA) rats. Methods SD
rats were divided randomly into six groups including normal, model, rhIL-1ra(7.5,30,120 mg·kg -1) and anakinra( 120 mg·kg -1) groups. Collagen Ⅱ emulsion was used to induce CIA model i n rats. The body weight was observed once a week. Paw
swelling of CIA rats was m easured with volume meter. CⅡ induced delayed-type hypersensitivity(DTH) was m easured. Meanwhile, the
level of anti-CⅡIgG
antibody in
serum was assayed by E LISA. Results The onset of paw swelling was on d10 after injection o f emulsion. The level of serum anti-CⅡIgG antibody was increased significantly in CIA. Pathological changes in joints of CIA rats showed hyperplastic synoviu m of CIA, inflammatory cells infiltration, pannus, destruction of cartilage and bone. rhIL-1ra(7.5,30,120 mg·kg -1·d -1×7 d) and anakinra(120 mg·kg -1·d -1×7 d) subcutaneous injection(sc) inhibited inflammat ory swelling. rhIL-1ra(30,120 mg·kg -1·d -1×7 d) significantly s uppressed the DTH reaction induced with CⅡ in CIA rats. Moreover,rhIL-1ra red uced the level of anti-CⅡ IgG antibody in serum. Pathological examination show ed rhIL-1ra(120 mg·kg -1·d -1×7 d) significantly improved subcho ndral inflammation, synovium hyperplasia, pannus and cartilage damage. Con clusion rhIL-1ra has therapeutic effects on CIA rats.
More abstracts about the Therapeutic effects of recombinant human interleukin 1 receptor antagonist on type Ⅱ collagen-induce